DDInter252 DDInter1840
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Bupropion {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Bupropion {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Bupropion {u} (Compound) upregulates {v} (Gene) KIT
KIT {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Bupropion {u} (Compound) upregulates {v} (Gene) GPER1
GPER1 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Bupropion {u} (Compound) downregulates {v} (Gene) HDAC6
HDAC6 {u} (Gene) regulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Bupropion {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Bupropion {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Bupropion {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Minoxidil
Minoxidil {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Bupropion (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Trabectedin (Compound)
Bupropion (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Trabectedin (Compound)
Bupropion (Compound) upregulates KIT (Gene) and KIT (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Bupropion may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Bupropion (Compound) upregulates GPER1 (Gene) and GPER1 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Bupropion may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Bupropion (Compound) downregulates HDAC6 (Gene) and HDAC6 (Gene) regulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Bupropion (Compound) downregulates MYC (Gene) and MYC (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) binds SRC (Gene) and Crizotinib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)